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Abstract
Background: Continuous Glucose Monitoring (CGM) has been in focus for treatment of diabetes. Recently, a
sensor-based flash glucose monitoring system, FreeStyle Libre (Abbott), has been introduced to clinical practice.
Case and results: The patient was 53 year-old female with type 1 diabetes mellitus (T1DM), who showed BMI
25.1 kg/m2, HbA1c 9.5% in January, 6.0% in June and 7.7% in November, 2017 as data on outclinic. CGM
measured glucose every 15 minutes in 24 hours for 14 days on June and November, and estimated HbA1c was
5.4% and 6.1%, respectively with discrepancy.
Discussion and conclusion: The beneficial points of FreeStyle Libre have been accurate, convenient and small
size for clinical use for lessen hypoglycemia episodes. Key benefits of CGM monitoring are frequency of testing,
trends, alarms, therapy optimization. Former studies for FreeStyle Libre tended to show lower values and larger
mean absolute relative difference (MARD) in lower range of glucose levels, suggesting possible cause of the
discrepancy for HbA1c levels. FreeStyle Libre for CGM would lead to better balance optimization of glucose control
and current results would become basal data for future investigation of CGM.
Keywords: Continuous glucose monitoring; FreeStyle libre; Type 1
diabetes mellitus; Mean absolute relative difference; Low carbohydrate
diet
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Introduction
The importance of controlling diabetic states has been emphasized
by several mega study such as Diabetes Control and Complications
Trial (DCCT) and Epidemiology of Diabetes Interventions and
Complications (EDIC) [1,2]. One of the effective research methods
would be the profile of blood glucose. Authors have reported clinical
studies concerning low carbohydrate diet (LCD) and investigated
glucose profile and related Morbus (M) value, indicating the efficacy of
LCD [3,4]. We also investigated the clinical significance of ketone
bodies in fetus, placenta, newborn and pregnant mother in the light of
LCD and glucose metabolism [5].
Continuous Glucose Monitoring (CGM) has been in focus for better
treatment of diabetes. CGM was reported at first by Updike et al. [6].
After that, electrodes for converting blood glucose concentration into
electric signals were devised, and several trials for CGM were
developed [7].
Consequently, Clinical and Laboratory Standards Institute (CLSI)
showed the guideline for CGM [8]. Consequently, reports have been
proposed concerning international standardization such as median
absolute relative deviation (MARD) and precision absolute relative
difference (PARD) [9,10].
Recently, a sensor-based flash glucose monitoring system has been
introduced to clinical practice using the flash glucose-sensing
technology, which is FreeStyle Libre (Abbott, USA) [11,12]. In this
study, blood glucose of patient with type 1 diabetes mellitus (T1DM)
was measured by FreeStyle Libre twice and investigated in detail.
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Case Presentation
The patient was 53 year-old female with type 1 diabetes mellitus
(T1DM) treated with insulin therapy for more than 10 years. She was
in rather uncontrolled condition during 2016 with the HbA1c from
9.1% to 11.5%. From January 2017, she was treated with our diabetic
program including both insulin therapy and education of carbohydrate
influence for blood glucose, which has been our medical and social
activity and movement for low carbohydrate diet (LCD) for several
years.
On physical examination, she showed 152 cm in height, 58 kg in
weight, BMI 25.1 kg/m2, abdominal circumference 89 cm, thigh
circumference 40 cm. Her vitals and consciousness are normal, and
lung, heart, abdomen and neurological findings were unremarkable.
Laboratory data on January 2017 were as follows: postprandial blood
glucose on 120 min. was 242 mg/dL, and HbA1c was 9.5%, AST 19
IU/mL, ALT 23 IU/mL, r-GT 25 IU/mL, Alb 4.6 mg/dL, Cre 0.64
mg/dL, Hb 15.4 g/dL, TSH 0.81 μIU/mL, free T4 1.26 ng/dL, HDL 37
mg/dL, LDL 89 mg/dL, TG 215 mg/dL.
The changes of postprandial blood glucose, HbA1c, insulin
treatment and body weight during 11 months are shown in Table 1.
HbA1c value decreased to 6.0% in June 2017, and after that increased
to 7.7% in November.
Time
Month in 2017 1 2 3 4 5 6 7 8 9 10 11
Glucose Examination            
Glucose-2 h (mg/dL) 242 140 123 184 123 109 95 108 182 194 165
HbA1c (%) 9.5 8.4 7.9 7.1 6.6 6.2 6.0 6.7 7.1 7.4 7.7
Insulin Treatment 
Apidora 07 h (unit) 23 23 22 19 16 12 9 10 11 13 16
Apidora 12 h (unit) 25 26 25 23 21 12 9 11 13 15 19
Apidora 18 h (unit) 25 26 24 22 20 14 11 13 14 16 19
Lantas 22 h (unit) 25 26 25 25 24 22 17 19 21 23 26
Body Weight
Body weight (kg) 58.5 56 55.7 55.5 54.6 55.7 55.2 54.9 55.2 56.3 56.9
Table 1: Changes of glucose, HbA1c and insulin treatment of the case.
CGM was performed twice in June and November in 2017 (Figure
1). We measured blood profile every 15 minutes in 24 hours for 14
days using FreeStyle Libre. It showed the changes of blood glucose
precisely. However, HbA1c level estimated from the data of CGM was
5.4% and 6.1%, respectively, which showed discrepancy with the
HbA1c level measured on outclinic, which was 6.0% and 7.7%,
respectively.
Sensor-based device for CGM
The sensor-based device for blood glucose monitoring was the
FreeStyle Libre Flash Glucose Monitoring system, produced by Abbott
Diabetes Care Inc, Alameda, CA, USA.
Its system was the first commercially available sensor systems using
factory-calibrated sensors which is the beneficial point [13,14]. It can
indicate for replacing blood glucose testing and detecting trends and
tracking patterns aiding in the detection of episodes of hyperglycemia
and hypoglycemia. Its characteristic points are accurate, convenient
and small size for clinical use [12,15]. The sensor is worn on the back
of the arm for up to 14 days and automatically stores glucose data
every 15 min [11,12,16,17].
Discussion
As to the treatment of T1DM, majority (>75%) of pediatric patient
do not meet International Society for Pediatric and Adolescent
Diabetes / American Diabetes Association guidelines for glycaemic
control (glycated Hb, 58 mmol/mol (7.5%) [18]. The problems include
HbA1c value and episodes of hypoglycemia which might be in severe
risk for life. Using FreeStyle Libre for 139 participants 6 months,
hypoglycemia was reduced by 50% with efficacy [16].
Schierenbeck compared and investigated two different CGM-
systems [19]. One is FreeStyle Libre subcutaneous continuous glucose
monitoring system (SC-CGM) and another is the Eirus intravascular
microdialysis continuous glucose monitoring system (MD-CGM). In
fact, both were reliable and used without complications [19].
Key benefits of CGM monitoring are frequency of testing, trends,
alarms, therapy optimization and diagnosis [14]. Similarly, guideline of
CLSI showed 7 important points, which are point accuracy, trend
accuracy, alarms, the stability of the sensor, calibration, time lag and
traceability [8].
In this study, there were discrepancy of HbA1c values twice. The
former was 6.0% vs 5.4%, and the latter was 7.7% vs. 6.1%, respectively.
The reason for discrepancy would include the possibilities as follows:
1) less carbohydrate intake due to nutritional education for LCD for
months, 2) psychologically less intake of carbohydrate during 14 days
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for CGM, 3) difficulty of capture for rapid and short time postprandial
hyperglycemia due to every 15 minute interval for CGM, 4) lower
glucose values in lower range of blood glucose <100 mg/dL on Libre
system (Figure 1).
Accuracy, safety and user acceptability of the FreeStyle libre System
were demonstrated for the 89 pediatric patients with T1DM [12]. On
contrast, Mean difference (SD) was reported to be -43.4 (20) mg/dL,
using FreeStyle Libre SC-CGM [19]. Furthermore, it tended to show
lower values in the lower ranges, and the underestimation of the effect
of meal on glucose response [20]. The mean absolute relative difference
(MARD) of glucose levels in range of <72, 72-180, <181 was 20.3%,
14.7%, 9.6%, respectively [21].
Linear regression analysis between the A1C and average glucose
values provided the tightest correlations, indicating the formula that
Average glucose (mg/dL) = 28.7 × A1c – 46.7, R =0.84 [22].
Taking these data into consideration, -43.4 / 28.7 equals to -1.5, in
which the estimated A1c calculated from CGM might be 1.5% lower in
lower range. From this standpoint, the discrepancy of HbA1c values, at
least in part, might be explained.
Conclusion
Diabetic management has been changing worldwide due to clinical
application of CGM, leading to better balance optimization of glucose
control with less risks of hypoglycemia [23]. The results in this study
would become basal data for future investigation of CGM in diabetic
patients.
Figure 1: Results of continuous glucose monitoring (CGM). a)
CGM data for 14 days in June, 2017. Estimated 5.4% in HbA1c
showed discrepancy with 6.0% in ordinary measurement in
outlinic. b) CGM data for 14 days in November, 2017. Estimated
6.1% in HbA1c showed discrepancy with 7.7% in ordinary
measurement in outlinic.
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